English
Frontpage Slideshow | Copyright © 2006-2011 JoomlaWorks Ltd.
News
  We are now recruiting patients with the indication chronic venous ulcer (CVU) for the clinical study in phase 1/2a. For more information click HERE.
  Review the latest article of Prof. Markus Frank: "ABCB5-targeted chemoresistance reversal inhibits Merkel cell carcinoma growth"
  Interesting article: "ABCB5 Identifies Immunoregulatory Dermal Cells"

RHEACELL GmbH & Co. KG

RHEACELL is dedicated to the development of pharmaceuticals based on ABCB5-positive mesenchymal stem cells.

As a licensee of a number of patents of Harvard University, Cambridge/USA, RHEACELL has worldwide exclusive rights to this technology. RHEACELL can make use of this technology when developing pharmaceuticals. Professor Markus Frank, Professor of Pediatrics and Dermatology at the Harvard Medical School, is assisting RHEACELL as scientific advisor. He has particular expertise in stem cell research.

Since mid-April 2016 RHEACELL is recruiting patients with the indication chronic venous ulcer (CVU) for the clinical study in phase 1/2a. The effect that ABCB5-positive cells from the skin have in the damaged tissue of CVU patients is studied multicentric at the University Hospital Würzburg.